Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.75% | 53.59 | 0.9% | $1398.09m | |
| JNJ | Johnson & Johnson | 0.02% | 179.49 | 0.7% | $1296.08m | |
| BMY | Bristol-Myers Squibb Co. | -2.64% | 75.55 | 1.0% | $1180.29m | |
| MRK | Merck & Co., Inc. | 0.19% | 92.49 | 0.7% | $1169.17m | |
| ABBV | AbbVie, Inc. | -1.23% | 148.72 | 1.9% | $1086.85m | |
| LLY | Eli Lilly & Co. | 1.98% | 319.65 | 1.1% | $986.32m | |
| AZN | AstraZeneca Plc | 0.53% | 67.06 | 1.0% | $494.16m | |
| BHVN | Biohaven Pharmaceutical Holding Co. Ltd. | 0.15% | 143.40 | 0.0% | $493.33m | |
| NVS | Novartis AG | -0.06% | 91.21 | 0.2% | $259.70m | |
| GSK | GlaxoSmithKline Plc | -1.08% | 43.94 | 0.2% | $254.81m | |
| VERU | Veru, Inc. | 0.12% | 12.66 | 0.0% | $254.11m | |
| HZNP | Horizon Therapeutics Plc | 3.83% | 94.06 | 5.4% | $203.54m | |
| SGEN | Seagen Inc. | 2.35% | 141.72 | 5.7% | $190.04m | |
| NVO | Novo Nordisk A/S | 0.66% | 107.30 | 0.1% | $184.06m | |
| VTRS | Viatris, Inc. | 1.54% | 12.20 | 0.0% | $167.88m |
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.